Invitrogen™ Zansecimab Recombinant Monoclonal Antibody

Zansecimab, also known as LY3127804, is a humanized IgG4 monoclonal antibody developed by Eli Lilly and Company, targeting angiopoietin 2 (Ang2). ANGPT2 (Angiopoietin-2) is a gene encoding a protein that plays a crucial role in angiogenesis, the process through which new blood vessels form from pre-existing vessels. Located on chromosome 8, ANGPT2 functions as a ligand for the TIE2 receptor, acting both as an agonist and antagonist depending on the physiological context. It disrupts the constitutive ANGPT1-TIE2 signaling, contributing to vascular destabilization and permeability, which is essential during inflammation and tumorigenesis. The regulation of ANGPT2 through alternative splicing and interactions with other angiogenic factors such as VEGF further modulates its role in pathological conditions, including cancer metastasis and inflammatory diseases. Inhibiting ANGPT2 has shown promise in preclinical studies as a strategy to reduce tumor growth and vascular complications.